scholarly journals Hypermethylation of the RASSF1A gene promoter as the tumor DNA marker for nasopharyngeal carcinoma

2021 ◽  
pp. 172460082110654
Author(s):  
Thuan Duc Lao ◽  
Hue Hong Thieu ◽  
Dung Huu Nguyen ◽  
Thuy Ai Huyen Le
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Meta Analysis ◽  
Scientific Evidence ◽  
Fixed Effect ◽  
Test Method ◽  
Control Group ◽  
Case Group ◽  
Early Screening ◽  
Rassf1a Gene ◽  
Rassf1a Methylation

Background RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with nasopharyngeal tumorigenesis. However, the heterogeneity was high among different studies. A meta-analysis was performed to evaluate the value of RASSF1A methylation for the diagnosis and early screening of nasopharyngeal carcinoma. Methods Relevant articles were identified by searching the MEDLINE database. Frequency and odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fixed-effect models. The meta-analysis was performed by using MedCalc® software. Subgroup analyses were performed by test method, ethnicity, and source of nasopharyngeal carcinoma samples to determine likely sources of heterogeneity. Results A total of 17 studies, including 1688 samples (1165 nasopharyngeal carcinoma samples, and 523 from non-cancerous samples) were used for the meta-analysis. The overall frequencies of RASSF1A methylation were 59.68% and 2.65% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among the studies included. The association between RASSF1A gene methylation and the risk of nasopharyngeal carcinoma was also confirmed by calculating the OR value of 30.32 (95%CI  = 18.22–50.47) in the fixed-effect model (Q = 16.41, p = 0.36,I 2  = 8.62, 95% CI = 0.00–45.27). Additionally, the significant association was also found between the methylation of the RASSF1A gene and the subgroups. Conclusions This is the first meta-analysis that has provided scientific evidence that the methylation of RASSF1A is the potential diagnosis, prognosis, and early screening biomarker for nasopharyngeal carcinoma.

scholarly journals Could the methylation of RASSF1A be the potential epigenetic biomarker for nasopharyngeal carcinoma? – Systematic review and meta-analysis

2020 ◽  
Author(s):  
Thuan Duc Lao ◽  
Hue Hong Thieu ◽  
Dung Huu Nguyen ◽  
Thuy Ai Huyen Le
Keyword(s):  
Meta Analysis ◽  
Suppressor Gene ◽  
Test Method ◽  
Control Group ◽  
Case Group ◽  
Gene Methylation ◽  
Early Screening ◽  
Effect Model ◽  
Epigenetic Biomarker ◽  
And Control

Abstract Background: RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with the nasopharyngeal tumorigenesis. However, the heterogeneity was high among different studies. This meta-analysis aimed to evaluate the value of RASSF1A methylation for diagnosing and early screening NPC. Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effect models. A meta-analysis was performed by using MedCalc® software. The subgroup analyses were performed by test-method, ethnicity, source of NPC samples to determine likely sources of heterogeneity. Results: Total of 16 studies, included 1,548 samples: 1,095 samples from NPC samples, and 453 from non-cancerous samples, were enrolled in the meta-analysis. The overall frequency of RASSF1A methylation were 59.22% and 1.72% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among included studies. The association between the RASSF1A gene methylation and risk of NPC was also confirmed by calculating OR value of 37.74 (95%OR = 20.07-70.98) in fix-effect model (Q = 13.56, p = 0.48, I2 = 0.00, 95% CI = 0.00-52.19). Additionally, the significant association was also found between the methylation of RASSF1A gene and subgroups. Conclusion: This was the first meta-analysis provided scientific evidences to suggest the RASSF1A methylation was the potential diagnosis, prognosis and early screening biomarker for NPC.

scholarly journals Could the methylation of RASSF1A be the potential epigenetic biomarker for nasopharyngeal carcinoma? – Systematic review and meta-analysis

2020 ◽  
Author(s):  
Thuan Duc Lao ◽  
Hue Hong Thieu ◽  
Dung Huu Nguyen ◽  
Thuy Ai Huyen Le
Keyword(s):  
Meta Analysis ◽  
Nasopharyngeal Cancer ◽  
Suppressor Gene ◽  
Test Method ◽  
Control Group ◽  
Case Group ◽  
Gene Methylation ◽  
Potential Biomarker ◽  
Epigenetic Biomarker ◽  
And Control

Abstract Background: RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with the nasopharyngeal tumorigenesis. Aiming to evaluate the association between the RASSF1A gene methylation and nasopharyngeal cancer, and its correlation could be used as an epigenetic biomarker for NPC cancer risk based on meta-analysis.Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effects models. Furthermore, subgroup analyses were performed by test-method, ethnicity, source of NPC samples.Results: Total of 16 studies, included 1,766 samples: 1,178 samples from NPC samples, and 588 samples from non-cancerous samples, were enrolled in the meta-analysis. The overall frequency of RASSF1A methylation were 55.98% and 1.70% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among included studies. The association between the RASSF1A gene methylation and risk of NPC was also confirmed by calculating OR value of 51.43 (95%OR = 28.12-94.08) in fix-effects model (Q = 10.63, p = 0.99, I2 = 0.00, 95% CI = 0.00-0.00). Additionally, the significant association was also found between the methylation of RASSF1A gene and subgroups.Conclusion: this was the first meta-analysis provided scientific evidences to suggest the RASSF1A methylation was the potential biomarker for risk of NPC.

scholarly journals Association between apolipoprotein gene polymorphisms and hyperlipidemia: a meta-analysis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xiao-Ning Zhao ◽  
Quan Sun ◽  
You-Qin Cao ◽  
Xiao Ran ◽  
Yu Cao
Keyword(s):  
Risk Factor ◽  
Cerebrovascular Disease ◽  
Gene Polymorphisms ◽  
Meta Analysis ◽  
Control Group ◽  
Case Group ◽  
Healthy Controls ◽  
Ε4 Allele ◽  
Different Populations ◽  
The Impact

Abstract Background Hyperlipidemia plays an important role in the etiology of cardio-cerebrovascular disease. Over recent years, a number of studies have explored the impact of apolipoprotein genetic polymorphisms in hyperlipidemia, but considerable differences and uncertainty have been found in their association with different populations from different regions. Results A total of 59 articles were included, containing in total 13,843 hyperlipidemia patients in the case group and 15,398 healthy controls in the control group. Meta-analysis of the data indicated that APOA5–1131 T > C, APOA1 -75 bp, APOB XbaI, and APOE gene polymorphisms were significantly associated with hyperlipidemia, with OR values of 1.996, 1.228, 1.444, and 1.710, respectively. All P-values were less than 0.05. Conclusions Meta-analysis of the data indicated that the C allele of APOA5 1131 T > C, the A allele at APOA1-75 bp, the APOB XbaI T allele, and the ε2 and ε4 allele of APOE were each a risk factor for susceptibility for hyperlipidemia.

scholarly journals The diagnostic value of EBV-DNA and EBV-related antibodies detection for nasopharyngeal carcinoma: a meta-analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Weixing Liu ◽  
Gui Chen ◽  
Xin Gong ◽  
Yingqi Wang ◽  
Yaoming Zheng ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Test Performance ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Cochrane Library ◽  
Control Group ◽  
Summary Receiver Operating Characteristic ◽  
Ebv Dna ◽  
The Difference ◽  
Sensitivity Specificity

Abstract Background Numerous individual studies have investigated the diagnostic value of EBV-DNA, EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG detection for nasopharyngeal carcinoma (NPC), but the conclusions remain controversial. This meta-analysis aimed to determine the value of EBV-DNA, EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG detection in the diagnosis of NPC. Methods PROSPERO registration number: CRD42019145532. PubMed, EMBASE, Cochrane Library, and Chinese data libraries (Wanfang, CNKI, and CBM) were searched up to January 2019. The pooled sensitivity, specificity, and positive likelihood, negative likelihood, and diagnostic odds ratios were conducted in this meta-analysis. Summary receiver operating characteristic curves evaluated the test-performance global summary. Publication bias was examined by Deek’s funnel plot asymmetry test. Results Forty-seven studies with 8382 NPC patients (NPC group) and 15,089 individuals without NPC (Control group) were included in this meta-analysis. The sensitivity, specificity, positive likelihood (+ LR), negative likelihood (-LR), DOR and AUC of EBV-DNA in diagnosis of NPC were: 0.76 (95% CI 0.73–0.77), 0.96 (95% CI 0.95–0.97), 14.66 (95% CI 9.97–21.55), 0.19 (95% CI 0.13–0.28), 84 (95% CI 50.45–139.88), 0.96 (SE: 0.001), and 0.55 (95% CI 0.54–0.57), 0.96 (95% CI 0.96–0.97), 12.91 (95% CI 9.55–17.45), 0.35 (95% CI 0.29–0.43), 39.57 (95% CI 26.44–59.23), 0.94 (SE: 0.002) for the EA-IgA, and 0.85 (95% CI 0.84–0.85), 0.89 (95% CI 0.88–0.89), 6.73 (95% CI5.38–8.43), 0.17 (95% CI 0.12–0.23), 43.03 (95% CI 31.51–58.76), 0.93 (SE: 0.007) for the VCA-IgA, and 0.86 (95% CI 0.85–0.88), 0.87 (95% CI 0.88–0.90), 7.55 (95% CI 5.79–9.87), 0.16 (95% CI 0.13–0.19), 50.95 (95% CI 34.35–75.57), 0.94 (SE: 0.008) for the EBNA1-IgA, and 0.70 (95% CI 0.69–0.71), 0.94 (95% CI 0.94–0.95), 9.84 (95% CI 8.40–11.54), 0.25 (95% CI 0.21–0.31), 40.59 (95% CI 32.09–51.35), 0.95 (SE: 0.005) for the Rta-IgG. The EBV-DNA had larger AUC compared with other EBV-based antibodies (P < 0.05), while the difference between EA-IgA, VCA-IgA, EBNA1-IgA and Rta-IgG was not statistically significant (P > 0.05). Conclusions EBV-DNA, VCA-IgA, EBNA1-IgA and Rta-IgG detection have high accuracy in early diagnosis NPC. In addition, EBV-DNA detection has the higher diagnosis accuracy in NPC. On the other hand, EA-IgA is suitable for the diagnosis but not NPC screening.

scholarly journals Association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility: A meta-analysis

2020 ◽  
Author(s):  
Roohollah Sharifi ◽  
Sajjad Jahedi ◽  
Hamid Reza Mozaffari ◽  
Mohammad Moslem Imani ◽  
Masuod Sadeghi ◽  
...  
Keyword(s):  
Dental Caries ◽  
Web Of Science ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
Case Group ◽  
Caries Risk ◽  
Increased Risk ◽  
Dental Caries Susceptibility ◽  
Review Manager

Abstract Background This meta-analysis evaluated the association of LTF, ENAM, and AMELX polymorphisms with dental caries susceptibility.Methods We searched the Scopus, PubMed/Medline, Web of Science, and Cochrane Library databases to retrieve articles published by October 2019. Review Manager 5.3 software was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs). The results of publication bias tests were retrieved by Comprehensive Meta-Analysis 2.0 software.Results A total of 150 relevant records were identified; out of which, 16 were entered into the analysis (4 studies assessed LTF, 11 ENAM, and 11 AMELX polymorphisms). Of all polymorphisms, there was a significant association only between ENAM rs3796704 polymorphism and dental caries susceptibility. Both ENAM rs3796704 and AMELX rs17878486 polymorphisms had a significant association with dental caries risk in the Caucasian ethnicity and the studies including caries-free control group.Conclusions The results of this meta-analysis showed that the G allele and the GG genotype of ENAM rs3796704 were associated with an increased risk of caries in the case group compared with the control group. But there was no association between LTF rs1126478, ENAM (rs1264848 and rs3796703), and AMELX (rs946252, rs17878486, and rs2106416) polymorphisms and dental caries susceptibility.

Antibiotic Prophylaxis for Thyroid and Parathyroid Surgery: A Systematic Review and Meta-analysis

2020 ◽  
pp. 019459982094770
Author(s):  
Fabio Medas ◽  
Gian Luigi Canu ◽  
Federico Cappellacci ◽  
Giorgio Romano ◽  
Giuseppe Amato ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antibiotic Prophylaxis ◽  
Science Studies ◽  
Negative Impact ◽  
Meta Analysis ◽  
Surgical Site Infections ◽  
Control Group ◽  
Case Group ◽  
Parathyroid Surgery ◽  
Duration Of Surgery

Objective Although thyroid and parathyroid surgery is considered a clean procedure with a low incidence of surgical site infections (SSIs), a great number of endocrine surgeons use antibiotic prophylaxis (AP). The aim of this study was to assess whether AP is significantly effective in reducing the incidence of SSIs in this kind of surgery. Data Sources A systematic literature search was performed with PubMed, Scopus, and ISI–Web of Science. Studies addressing the efficacy of AP in reducing the incidence of SSIs in thyroid and parathyroid surgery were included in the systematic review and meta-analysis. Review Methods The random effects model was assumed to account for different sources of variation among studies. The overall effect size was computed through the inverse variance method. Heterogeneity across studies, possible outlier studies, and publication bias were evaluated. Results A total of 6 studies with 4428 patients were included in the quantitative analysis. The incidence of SSI was 0.6% in the case group and 0.4% in the control group (odds ratio, 1.07; 95% CI, 0.3-3.81; P = .915). There was no evidence of heterogeneity among the studies ( Q = 8.36, P = .138; I2 = 40.17). The analysis of several continuous moderators, including age, use of drain, and duration of surgery, did not generate any significant result. Conclusion AP is not effective in reducing the incidence of SSI in thyroid and parathyroid surgery and should be avoided, notwithstanding the negative impact on social costs and the risk of development of antibiotic resistance.

scholarly journals The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Ehsan Alimohammadi ◽  
Seyed Reza Bagheri ◽  
Shahram Taheri ◽  
Maliheh Dayani ◽  
Alireza Abdi
Keyword(s):  
Overall Survival ◽  
Glioblastoma Multiforme ◽  
Maintenance Therapy ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Control Group ◽  
Case Group ◽  
Free Survival ◽  
Upper Limits ◽  
The Impact

Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy is the current standard treatment for glioblastoma multiforme (GBM). The present metaanalysis investigated the impact of prolonged TMZ maintenance therapy (more than 6 cycles) in comparison with standard TMZ maintenance therapy (exactly six cycles) on overall survival (OS) and progression-free survival (PFS) of patients with GBM. A meta-analysis of the literature was conducted using Medline, PubMed, EMBASE and the Cochrane Library in accordance with PRISMA guidelines. Seven articles involving 1018 patients were included. The overall survival was higher in the case group (>6 cycles TMZ) compared to the control group (6 cycles TMZ) (Z=2.375, P=0.018). The lower and upper limits were between 1.002-10.467 months. The case group had higher progression-free survival compared with the control group (Z=3.84; P<0.001). The lower and upper limits were between 2.559-7.894 months. Evidence from this meta-analysis suggests that prolonged TMZ therapy compared to the standard 6-cycle TMZ therapy was associated with higher survival in patients with glioblastoma.

scholarly journals Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis

2019 ◽  
Vol 11 ◽  
pp. 1759720X1985851 ◽  
Author(s):  
Railson de Oliveira Ferreira ◽  
Raíra de Brito Silva ◽  
Marcela Baraúna Magno ◽  
Anna Paula Costa Ponte Sousa Carvalho Almeida ◽  
Nathália Carolina Fernandes Fagundes ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Risk Factor ◽  
Quantitative Analysis ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Control Group ◽  
Case Group ◽  
Eligibility Criteria ◽  
Inflammatory Profile

Periodontitis is an inflammatory disease of dental supporting tissues (gingiva, periodontal ligament, and bone) and it has been suggested as a possible etiology for rheumatoid arthritis (RA). In this systematic review, we aim to verify if periodontitis represents a risk factor for RA. Electronic databases were consulted until March 2018 considering eligibility criteria focusing on: (P, participants) adults; (E, exposure) with periodontitis; (C, comparison) without periodontitis; and (O, outcome) development of RA. Quality assessment of studies and risk-of-bias evaluation were also performed. To undertake a quantitative analysis, the number of persons with RA and a total number of participants for the case group (with periodontitis) and control group (without periodontitis) were used to calculate the odds ratio (OR) with a 95% confidence interval (CI). A total of 3888 articles were identified, and nine studies were considered eligible. Seven of 9 articles suggested an association among diseases by the common pro-inflammatory profiles. The pooled analysis of 3 articles showed a higher RA prevalence for persons with periodontitis ( n = 1177) than controls ( n = 254) (OR 1.97; CI 1.68–2.31; p < 0.00001). However, considerable heterogeneity among studies was verified (I2 = 96%, p < 0.00001). Periodontitis may represent a risk factor for RA by heredity, bacterial infection, and the pro-inflammatory profile shared between both diseases. Although most of the elective studies report an association between periodontitis and RA, the quantitative analysis showed a high heterogeneity, leading to the need for further studies.

scholarly journals Association Between Apolipoprotein Gene Polymorphisms and Hyperlipidemia: A Meta-analysis

2020 ◽  
Author(s):  
Xiao-Ning Zhao ◽  
Quan Sun ◽  
You-Qin Cao ◽  
Xiao Ran ◽  
Yu Cao
Keyword(s):  
Systematic Review ◽  
Gene Polymorphisms ◽  
Meta Analysis ◽  
Case Control ◽  
Control Group ◽  
Case Group ◽  
Case Control Studies ◽  
Quality Of Data ◽  
Different Populations ◽  
The Impact

Abstract Background: Hyperlipidemia plays an important role in the etiology of cardio-cerebrovascular disease. Over recent years, a number of studies have explored the impact of apolipoprotein genetic polymorphisms in hyperlipidemia, but considerable differences and uncertainty have been found in their association for different populations from different regions. Objective: To correlate apolipoprotein gene expression with hyperlipidemia through a systematic review of case-control studies. Methods: Comprehensive identification of relevant articles in Pubmed, Web of Science, ScienceDirect, CNKI, Wangfang, and VIP published to June 9, 2020. A systematic review of hyperlipidemia case-control studies was conducted to evaluate the quality of data in articles included in the review, and a meta-analysis was conducted using Stata 11 software. Results: A total of 59 articles were included, containing in total 13843 hyperlipidemia patients in the case group and 15398 healthy controls in the control group. Meta-analysis of the data indicated that APOA5-1131T>C, APOA1 -75bp, APOB XbaⅠand APOE gene polymorphisms were significantly associated with hyperlipidemia, with OR values of 1.996, 1.228, 1.444 and 1.710, respectively, for allele models. All P values were less than 0.05. Conclusions: Meta-analysis of the data indicated that the C allele of APOA5 1131T>C, the A allele at APOA1-75bp, the APOB XbaⅠ T allele, and the ε4 allele of APOE were each a risk factor for susceptibility for hyperlipidemia.

scholarly journals Utility of perfusion imaging in acute stroke treatment: a systematic review and meta-analysis

2016 ◽  
Vol 9 (10) ◽  
pp. 1012-1016 ◽  
Author(s):  
Won Hyung A Ryu ◽  
Michael B Avery ◽  
Navjit Dharampal ◽  
Isabel E Allen ◽  
Steven W Hetts
Keyword(s):  
Systematic Review ◽  
Acute Stroke ◽  
Perfusion Imaging ◽  
Meta Analysis ◽  
Scientific Evidence ◽  
Intervention Group ◽  
Cochrane Library ◽  
Control Group ◽  
Eligibility Criteria ◽  
Stroke Treatment

BackgroundVariability in imaging protocols and techniques has resulted in a lack of consensus regarding the incorporation of perfusion imaging into stroke triage and treatment. The objective of our study was to evaluate the available scientific evidence regarding the utility of perfusion imaging in determining treatment eligibility in patients with acute stroke and in predicting their clinical outcome.MethodsWe performed a systematic review of the literature using PubMed, Web of Science, and Cochrane Library focusing on themes of medical imaging, stroke, treatment, and outcome (CRD42016037817). We included randomized controlled trials, cohort studies, and case-controlled studies published from 2011 to 2016. Two independent reviewers conducted the study appraisal, data abstraction, and quality assessments of the studies.ResultsOur literature search yielded 13 studies that met our inclusion criteria. In total, 994 patients were treated with the aid of perfusion imaging compared with 1819 patients treated with standard care. In the intervention group 51.1% of patients had a favorable outcome at 3 months compared with 45.6% of patients in the control group (p=0.06). Subgroup analysis of studies that used multimodal therapy (IV tissue plasminogen activator, endovascular thrombectomy) showed a significant benefit of perfusion imaging (OR 1.89, 95% CI 1.43 to 2.51, p<0.01).ConclusionsPerfusion imaging may represent a complementary tool to standard radiographic assessment in enhancing patient selection for reperfusion therapy, with a subset of patients having up to 1.9 times the odds of achieving independent functional status at 3 months. This is particularly important as patients selected based on perfusion status often included individuals who did not meet the current treatment eligibility criteria.

Sign in / Sign up

Export Citation Format

Share Document